Sanofi Consumer

Why is Sanofi Consumer Healthcare India Ltd falling/rising?

As of 29-Aug, Sanofi Consumer Healthcare India Ltd's stock is rising to 4,213.65, up 1.37%. Despite recent gains and strong quarterly results, the stock has a -17.34% return over the past year and faces long-term performance challenges.

As of 29-Aug, Sanofi Consumer Healthcare India Ltd's stock price is rising, currently at 4,213.65, reflecting a change of 56.8 (1.37%) upward. This increase can be attributed to several factors. Firstly, the stock has outperformed its sector by 1.08% today and has shown a consecutive gain over the last two days, with a total return of 1.9% during this period. Additionally, the stock reached an intraday high of Rs 4,299, indicating positive trading momentum.<BR><BR>Despite the recent rise, it is important to note that the stock has faced challenges in the longer term. Over the past year, it has generated a return of -17.34%, and its performance has been below par compared to the BSE500 index over various time frames. However, the company has demonstrated strong fundamentals, including high management efficiency with a return on equity (ROE) of 67.74%, and it is net-debt free. Furthermore, the company has reported positive results for the last four consecutive quarters, with net sales growing at 26.89% over the last nine months.<BR><BR>In summary, while the stock is currently rising due to short-term positive performance and strong quarterly results, it faces long-term challenges that have affected its overall performance.

Which are the latest news on Sanofi Consumer?

What does Sanofi Consumer do?

Sanofi Consumer Healthcare India Ltd, established in May 2023, focuses on consumer healthcare following a demerger from Sanofi India Limited. As of June 2026, it reported net sales of 236 Cr and a net profit of 69 Cr, with a market cap of INR 10,243 Cr.

Overview: <BR>Sanofi Consumer Healthcare India Ltd operates in the Pharmaceuticals & Biotechnology industry as a small-cap company focused on consumer healthcare.<BR><BR>History: <BR>The company was incorporated on May 10, 2023, as part of Sanofi's strategy to establish a standalone Consumer Healthcare business following the demerger from Sanofi India Limited. The latest quarterly results reported net sales and profit for June 2026.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 236 Cr (Quarterly Results - Jun 2026) <BR>Most recent Net Profit: 69 Cr (Quarterly Results - Jun 2026) <BR>Market-cap value: INR 10,243 Cr (Small Cap)<BR><BR>Key Metrics: <BR>P/E: 38.00 <BR>Industry P/E: 37 <BR>Dividend Yield: 1.67% <BR>Debt Equity: -0.98 <BR>Return on Equity: 69.27% <BR>Price to Book: 26.96 <BR><BR>Contact Details: <BR>Registrar Address: Not available. <BR>Phone: N/A <BR>Email: N/A <BR>Website: N/A

Who are the peers of the Sanofi Consumer?

Sanofi Consumer's peers include Akums Drugs, Viyash Scientifi, Blue Jet Health, Orchid Pharma, P & G Health Ltd, Strides Pharma, Aarti Pharma, and Sanofi India. Akums Drugs leads in 1-year returns at 54.02%, while Sanofi India has the lowest at -35.74%, with Sanofi Consumer's return at -12.44%.

Peers: The peers of Sanofi Consumer are Akums Drugs, Viyash Scientifi, Blue Jet Health, Orchid Pharma, P & G Health Ltd, Strides Pharma, Aarti Pharma, and Sanofi India.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sanofi Consumer, Akums Drugs, P & G Health Ltd, and Sanofi India, while Average management risk is found at Strides Pharma and Aarti Pharma, and the rest. Below Average management risk is noted at Viyash Scientifi, Orchid Pharma. In terms of Growth, Good growth is seen at Viyash Scientifi and Strides Pharma, while Average growth is found at Akums Drugs, Aarti Pharma, and the rest, and Below Average growth is noted at Blue Jet Health, Sanofi Consumer, Orchid Pharma, P & G Health Ltd, and Sanofi India. Excellent capital structure is observed at Akums Drugs, Blue Jet Health, Sanofi Consumer, P & G Health Ltd, Aarti Pharma, and Sanofi India, while Average capital structure is found at Strides Pharma, and Below Average capital structure is noted at Viyash Scientifi, Orchid Pharma.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Akums Drugs at 54.02%, while the peer with the lowest is Sanofi India at -35.74%, indicating that Sanofi Consumer's 1-year return of -12.44% is better than Sanofi India but worse than Akums Drugs. Additionally, Sanofi India and P & G Health Ltd have negative six-month returns.

How big is Sanofi Consumer?

As of 14th August, Sanofi Consumer Healthcare India Ltd has a market capitalization of 10,227.90 Cr and reported net sales of 949.80 Cr and net profit of 266.00 Cr over the latest four quarters.

As of 14th August, <BR><BR>Market Cap: Sanofi Consumer Healthcare India Ltd has a market capitalization of 10,227.90 Cr, categorized as Small Cap.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters is 949.80 Cr, while the sum of Net Profit for the same period is 266.00 Cr.<BR><BR>Balance Sheet Snapshot: The reporting period for the balance sheet is December 2025. Shareholder's Funds are valued at 384.00 Cr, and Total Assets amount to 538.50 Cr.

Should I buy, sell or hold Sanofi Consumer Healthcare India Ltd?

Are Sanofi Consumer Healthcare India Ltd latest results good or bad?

Sanofi Consumer Healthcare India Ltd's latest Q1 FY27 results show a net profit increase of 13.35% year-on-year and revenue growth of 6.70%. However, a decline in operating margin to 37.89% raises concerns about profitability amid rising costs.

Sanofi Consumer Healthcare India Ltd's latest results for Q1 FY27 show a mixed performance. On the positive side, the company reported a net profit of ₹68.80 crores, which is a 13.35% increase year-on-year and a 1.47% increase quarter-on-quarter. Revenue also grew by 6.70% year-on-year, reaching ₹235.70 crores, with a sequential growth of 2.84%.<BR><BR>However, there are concerns regarding the operating margin, which declined by 85 basis points to 37.89% compared to the previous quarter. This margin compression indicates challenges in maintaining profitability amidst rising costs and competitive pressures. <BR><BR>Overall, while the company has demonstrated strong profitability and growth in net profit and revenue, the decline in operating margin suggests that it is facing some headwinds. Investors should monitor these trends closely, especially the impact on margins moving forward.

When is the next results date for Sanofi Consumer Healthcare India Ltd?

The next results date for Sanofi Consumer Healthcare India Ltd is 28 July 2026.

The next results date for Sanofi Consumer Healthcare India Ltd is scheduled for 28 July 2026.

Is Sanofi Consumer technically bullish or bearish?

As of December 2, 2025, Sanofi Consumer's technical trend has shifted to a bearish stance, driven by bearish MACD, Bollinger Bands, and moving averages, despite some divergence in longer-term perspectives indicated by Dow Theory.

As of 2 December 2025, the technical trend has changed from mildly bearish to bearish. The current stance is bearish with moderate strength. Key indicators driving this include a bearish MACD on the weekly timeframe, bearish signals from Bollinger Bands, and bearish moving averages on the daily timeframe. Additionally, the KST is bearish on the weekly, and the OBV shows a mildly bearish trend. The Dow Theory indicates a mildly bearish stance on the weekly but is mildly bullish on the monthly, suggesting some divergence in longer-term perspectives. Overall, the bearish indicators dominate the current technical outlook for Sanofi Consumer.

How has been the historical performance of Sanofi Consumer?

Sanofi Consumer reported net sales of 724.50 crore and a profit after tax of 181.00 crore for the year ending December 2024, reflecting strong growth. Shareholder's funds increased to 273.00 crore, and cash and bank balances rose significantly to 326.90 crore.

Answer:<BR>The historical performance of Sanofi Consumer for the year ending December 2024 shows significant growth in various financial metrics compared to the previous year.<BR><BR>Breakdown:<BR>In December 2024, Sanofi Consumer reported net sales of 724.50 crore, with total operating income also at 724.50 crore. The total expenditure, excluding depreciation, was 453.90 crore, leading to an operating profit (PBDIT) of 283.60 crore. After accounting for interest and exceptional items, the profit before tax stood at 246.80 crore, resulting in a profit after tax of 181.00 crore. The earnings per share (EPS) was reported at 78.7, with a PAT margin of 24.98%. On the balance sheet, shareholder's funds increased to 273.00 crore from 207.60 crore in the previous year, while total liabilities rose to 425.10 crore from 343.50 crore. The total assets also increased to 425.10 crore, with cash and bank balances significantly rising to 326.90 crore from just 1.60 crore in December 2023. The cash flow from operating activities was 439.00 crore, contributing to a net cash inflow of 325.00 crore for the year.

Is Sanofi Consumer overvalued or undervalued?

As of April 19, 2025, Sanofi Consumer is considered very expensive and overvalued with a PE ratio of 57.64, significantly higher than its peers, and has underperformed the Sensex with a recent return of -6.91%.

As of 19 April 2025, the valuation grade for Sanofi Consumer has moved from does not qualify to very expensive, indicating a significant shift in its perceived value. The company is currently overvalued, with a price-to-earnings (PE) ratio of 57.64, a price-to-book value of 42.77, and an EV to EBITDA ratio of 41.78. These ratios suggest that the stock is trading at a premium compared to its earnings and book value.<BR><BR>In comparison to its peers, Sanofi Consumer's PE ratio is notably higher than Sun Pharmaceutical Industries Ltd. at 35.25 and Cipla Ltd. at 22.99, both of which are considered attractive. Furthermore, the PEG ratio for Sanofi is 0.00, indicating no growth expectations, which contrasts sharply with the more reasonable valuations of its competitors. Recent stock performance shows that Sanofi has underperformed the Sensex over the past week, with a return of -6.91% compared to the Sensex's 1.35%. This reinforces the notion that the stock may be overvalued in the current market context.

Who are the top shareholders of the Sanofi Consumer?

The top shareholders of Sanofi Consumer include Opella Healthcare Participations B.V. with 60.4%, Life Insurance Corporation of India at 5.66%, and individual investors with 6.58%. Additionally, 18 mutual fund schemes hold 15.09%, while 102 foreign institutional investors have a total of 4.53%.

The top shareholders of Sanofi Consumer include Opella Healthcare Participations B.V., which holds the largest stake at 60.4%. Other significant shareholders are the Life Insurance Corporation of India, with a holding of 5.66%, and individual investors collectively owning 6.58%. Additionally, the company has 18 mutual fund schemes holding a combined 15.09% and 102 foreign institutional investors (FIIs) with a total holding of 4.53%. There are no pledged promoter holdings reported.

Has Sanofi Consumer declared dividend?

Yes, Sanofi Consumer Healthcare India Ltd has declared a 550% dividend, amounting to ₹55 per share, with an ex-date of April 17, 2025. However, total returns over the past year and longer periods have been stagnant, showing no price or dividend growth.

Sanofi Consumer Healthcare India Ltd has declared a 550% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 550%<BR>- Amount per share: 55<BR>- Ex-date: 17 Apr 25<BR><BR>Dividend Yield: 1.08%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was 5.2%, the dividend return was 1.14%, resulting in a total return of 6.34%.<BR><BR>In the last 1 year, there was no price return or dividend return, leading to a total return of 0.0%.<BR><BR>In the last 2 years, there was no price return or dividend return, resulting in a total return of 0.0%.<BR><BR>In the last 3 years, there was no price return or dividend return, leading to a total return of 0.0%.<BR><BR>In the last 4 years, there was no price return or dividend return, resulting in a total return of 0.0%.<BR><BR>In the last 5 years, there was no price return or dividend return, leading to a total return of 0.0%.<BR><BR>Overall, while Sanofi Consumer has declared a significant dividend, the total returns over longer periods indicate a lack of growth in price and dividends, suggesting a mixed performance in terms of shareholder returns.